Nodis

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nodis

Quick Facts About Nodis (Rosuvastatin)

Property Description
Active ingredient Rosuvastatin Calcium (INN)
Form Oral Film-coated tablet (Prescription-only)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Lipid-lowering agent
Origin Synthetic compound

What is the Drug Class and Active Ingredient of Nodis?

Nodis is a synthetic, prescription-only pharmaceutical entity, fundamentally defined by its active ingredient, Rosuvastatin (INN), typically present as rosuvastatin calcium. This medicine is formally classified as a HMG-CoA Reductase Inhibitor, placing it within the broader drug class of Statins. Rosuvastatin is chemically differentiated from older statins by being a fully synthetic and hydrophilic molecule. This unique structure is characterized by a high binding affinity for the HMG-CoA reductase enzyme, which enhances its overall potency.

What is the Physical Form and Composition of Nodis?

Nodis is supplied for therapeutic use as a solid, orally administered medication, commonly available as a film-coated tablet. It is a single-ingredient product, featuring the active Rosuvastatin Calcium combined with various inactive excipients that form the stable dosage vehicle. Unlike some related statins, Rosuvastatin is predominantly delivered via the oral tablet route of administration, with a composition optimized for systemic absorption that specifically targets the liver for its therapeutic action.

What is the General Therapeutic Purpose of Nodis?

The overarching purpose of Nodis is to serve as a potent lipid-lowering agent to strategically manage and rebalance blood fats. It functions by implementing a production blockade of cholesterol synthesis in the liver, while simultaneously enhancing the hepatic clearance of harmful low-density lipoprotein cholesterol (LDL-C). Through the reduction of LDL-C levels, the drug serves as a component in the long-term management of high cholesterol, primarily by supporting improved cardiovascular health.

Regulatory References

  1. Rosuvastatin - LiverTox - NCBI Bookshelf - NIH
  2. Cardiovascular disease: risk assessment and reduction, including lipid modification - NICE Guideline NG238

What side effects are possible with Nodis?

Possible side effects and safety information

The safety profile of Nodis (Rosuvastatin) is formally classified by regulatory agencies based on incidence rates and affected body systems. The documented adverse reactions range from common, expected events to rare, serious concerns.

Adverse Reaction Frequencies

Adverse reactions are categorized using established regulatory frequency bands:

  • Common (occurring in 1/100 to 1/10 people): Reactions frequently reported in clinical trials include headache, myalgia (muscle pain), asthenia (weakness), constipation, nausea, and abdominal pain.
  • Uncommon (occurring in 1/1,000 to 1/100 people): Includes some hypersensitivity reactions such as rash and itching (pruritus).
  • Rare (occurring in 1/10,000 to 1/1,000 people): Includes rhabdomyolysis (severe muscle breakdown), pancreatitis, and severe hypersensitivity reactions like angioedema.

System-Organ Classes and Serious Reactions

The most critical areas of safety focus are the Musculoskeletal and Hepatobiliary systems. Serious adverse reactions documented in regulatory sources include Rhabdomyolysis and rare reports of fatal or non-fatal Hepatic Failure.

Postmarketing reports have also noted rare cases of Immune-Mediated Necrotizing Myopathy (IMNM) and cognitive impairment (such as memory loss or confusion), which are generally non-serious and reversible.

Safety Considerations for Specific Populations

Safety limitations are defined for certain patient groups. Use is formally contraindicated in women who are pregnant or breastfeeding and in patients with active liver disease. Furthermore, specific safety notes apply to patients with severe renal impairment and individuals of Asian descent, where increased systemic exposure has been documented. The risk of muscle toxicity is also noted to be higher for patients over 65 years old.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Nodis (Rosuvastatin) indicates that there is no specific treatment or symptom profile uniquely associated with an overdose. Manifestations are generally expected to be an exaggeration of the drug’s known adverse effects.


Documented Risks and Outcomes

Classification Official Regulatory Statement
Documented Manifestations Symptoms may relate to myopathy (muscle disease) and markedly elevated Creatine Kinase (CK) levels
Serious Outcomes Potential for Rhabdomyolysis (severe muscle breakdown) and resultant Acute Renal Failure

Official Emergency Response

Aspect Official Regulatory Statement
Immediate Action Seek immediate medical attention; Contact your regional poison control centre, or go to the nearest hospital emergency room right away
Antidote/Clearance No specific antidote is available; Hemodialysis does not significantly enhance clearance
Management Treatment must be symptomatic and supportive measures instituted as required

The regulatory profile mandates that any suspected overdose requires urgent professional evaluation and supportive care. The lack of an antidote and the ineffectiveness of hemodialysis for clearance underscore the necessity for immediate hospital monitoring to manage potential severe complications like acute renal failure.

Therapeutic Uses of Nodis

What Nodis Treats: Main Uses and Benefits

Nodis is commonly used to manage lipid imbalances associated with systemic cardiovascular factors. The primary therapeutic goals are to manage high cholesterol and support risk reduction related to the heart and blood vessels. The medication is typically applied in contexts where additional supportive symptom management is appropriate.

Addressing Lipid Imbalances and High Cholesterol

The medicine is relevant for managing symptoms related to systemic imbalance, including high cholesterol and related conditions. It is applied in addressing conditions characterized by periods of heightened symptoms, such as certain inherited forms of high cholesterol. By managing these systemic symptoms, Nodis supports general well-being during symptomatic phases. The medicine assists with maintaining functional stability during symptomatic periods.

Supporting Cardiovascular Health

Nodis supports patients in addressing conditions where functional stability becomes affected by systemic imbalance. It is relevant in contexts involving heightened systemic burden and assists with maintaining functional stability. Consistent use helps manage these symptoms and supports the patient during difficult episodes by easing distress.

Quick Fact: Support for Conditions Involving Systemic Stress
Nodis is commonly used to help with conditions characterized by periods of heightened symptoms.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Nodis (Rosuvastatin)

Nodis (Rosuvastatin) is a prescription medicine whose use is defined by regulatory bodies through specific constraints related to patient conditions and demographics. Eligibility falls into three main regulatory categories: allowed, restricted, and contraindicated.

Classification Population or Condition Status
Absolute Contraindications Active liver disease Must Not Use
Pregnancy or Lactation Must Not Use
Known Hypersensitivity to the drug Must Not Use
Concomitant use of Ciclosporin Must Not Use
Conditional Use / Restrictions Severe Renal Impairment (CrCl < 30 mL/min) Use is Strictly Limited
Patients of Asian Descent Special Consideration Required
Factors Pre-disposing to Myopathy Use with Caution

Age-Related Eligibility

The medicine is approved for use in adults and for specific inherited forms of high cholesterol in pediatric patients starting from age six or seven, depending on the specific condition and regulatory region. However, safety and efficacy are officially not established for children younger than this approved age range.

Reproductive Status

Nodis is contraindicated during pregnancy, and women of childbearing potential are officially advised to use effective contraception throughout the duration of the treatment. Use during breastfeeding is also not recommended due to potential risks to the infant, as stated in regulatory documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nodis (rosuvastatin) interactions are officially documented to occur primarily through the inhibition of specific drug transporters (OATP1B1 and BCRP), which are responsible for its uptake and clearance. This mechanism leads to an increase in rosuvastatin exposure, a form of pharmacokinetic interaction, when co-administered with certain medicines.

Formal Restrictions and Exposure Alterations

Co-administration with Cyclosporine or Darolutamide significantly increases rosuvastatin exposure; in these cases, regulatory labels mandate that the Nodis dose must not exceed 5 mg once daily. Similarly, concomitant use with certain Antivirals (such as Lopinavir/ritonavir or Glecaprevir/pibrentasvir) restricts the maximum Nodis dose to 10 mg once daily.

Pharmacodynamic and Timing Interactions

  • Coumarin Anticoagulants (e.g., Warfarin): Co-administration results in the prolongation of the International Normalized Ratio (INR), requiring mandated monitoring upon initiation or dose change.
  • Gemfibrozil and Colchicine: The official profile notes that the combination with Gemfibrozil should generally be avoided, and co-administration with Colchicine increases the documented risk of skeletal muscle effects.
  • Aluminum and Magnesium Hydroxide Antacids: A mandatory timing rule requires Nodis to be administered at least 2 hours before the antacid to prevent a reduction in rosuvastatin plasma concentration.

Mechanism of Action

Mechanism: How Nodis Works

Nodis (Rosuvastatin) initiates its action by acting as a competitive inhibitor of the enzyme HMG-CoA Reductase within the liver cells. This enzyme controls the rate-limiting step in the mevalonate pathway, which is responsible for the body's natural synthesis of cholesterol. The mechanism thus creates an immediate barrier to the endogenous production of cholesterol.

The resulting drop in cellular cholesterol triggers a crucial biological feedback mechanism: the liver cell increases the expression of Low-Density Lipoprotein (LDL) receptors on its surface. This massive upregulation enhances the liver's capacity to actively capture and remove LDL-C and VLDL particles directly from the systemic circulation, accelerating the clearance rate of these lipoproteins from the blood.

Beyond its core lipid effects, the drug's inhibition of the mevalonate pathway also depletes the synthesis of isoprenoid signaling molecules. This modulation is mechanistically linked to secondary, pleiotropic effects, including modulation of endothelial function and modulation of certain inflammatory processes within the blood vessel walls, contributing to the overall physiological effects.

Dosage and Administration Information

Nodis is approved for oral administration as a film-coated tablet, used as part of a long-term chronic therapy plan. The medication is dosed once daily and can be taken with or without food at any time of the day.

Administration and Dosing

Therapy typically begins with a dose of 10 mg or 20 mg once daily. The available strengths are 5 mg, 10 mg, 20 mg, and 40 mg. The standard protocol requires that dosage adjustments, if necessary, be made at intervals of 2 to 4 weeks based on assessment. The maximum recommended dose is 40 mg once daily, which is generally reserved for patients who have not achieved their treatment goals on the 20 mg strength.

Specific Procedural Conditions

Specific population-based instructions govern the initiation of therapy. For instance, patients with severe renal impairment who are not on dialysis must not exceed 10 mg once daily, with a recommended starting dose of 5 mg. A starting dose of 5 mg should also be considered for patients of Asian ancestry. The tablet must be swallowed whole.

Handling Missed Doses and Co-administration

A procedural constraint specifies that if a patient needs to take an antacid containing aluminum or magnesium hydroxide, it must be taken 2 hours after the dose of Nodis. If a dose is missed, it should be skipped, and the patient should resume the treatment schedule at the usual time.

Recent Clinical Evidence

Research evidence / Overview of studies for Nodis

Evidence for the Management of High Cholesterol (Hypercholesterolemia)

Research examined the medicine for its use in conditions involving lipid imbalances. Studies were conducted in short- to medium-term Randomized Controlled Trials (RCTs). These trials monitored changes in blood fat biomarkers; some compared the medicine against a placebo (an inactive treatment) or other therapies.

Research was applied in studies examining outcomes related to systemic or functional imbalance; studies monitored changes in Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and Triglyceride levels over defined time intervals. Studies tracked the percentage of participants whose LDL-C levels reached predefined levels. This research provides context regarding lipid level patterns observed in the studies.

Evidence for Supporting Cardiovascular Health (Primary Prevention)

Research was conducted to examine the medicine's use in individuals without heart disease to see if it was associated with differences in the rate of first-time major cardiovascular events in adults identified as being at increased risk. This risk sometimes included elevated levels of the inflammation biomarker, C-reactive protein (hsCRP).

Findings describe patterns observed in the studies for the occurrence of these events over the study duration. A key limitation is that the results apply only to the specific, often narrowly defined, high-risk populations studied in these large trials, meaning that long-term effects beyond this period are not fully established based on the primary RCT data.

Research Gaps and Areas of Uncertainty

One research limitation is that the data related to lipid modification often relies on short-term trials and the use of biomarker changes (surrogate outcomes), rather than primary long-term clinical event data, as the main endpoint.

Evidence highlights what is known—and what is still uncertain—about Nodis. Long-term effects over 10 or 20 years are not fully established by continuous, single-drug RCTs, and data for these periods are still emerging.

Frequently Asked Questions (FAQ)

Common questions about Nodis (FAQ)

Q: How does Nodis differ from older or more established medications for the same condition?

Official product information describes Nodis as a synthetic and hydrophilic compound, which is chemically different from some older medicines in the same class. This unique structure is chemically recognized for affording it a high binding affinity for the target enzyme, contributing to its intended efficacy.


Q: What are the signs of a serious or uncommon side effect of Nodis?

Serious side effects related to muscle breakdown, called rhabdomyolysis, may include unexplained muscle pain, tenderness, or weakness, especially if accompanied by dark urine. Signs associated with potential liver issues include unexplained fatigue, dark urine, or yellowing of the skin or eyes. These are described in the official warnings and precautions for the medication.


Q: Will Nodis affect my ability to drive, focus, or operate machinery?

Dizziness is noted as an adverse reaction. In post-marketing reports, instances of cognitive impairment (such as confusion or memory loss) have also been noted. If these effects occur, official labels advise caution when engaging in activities that require full alertness, such as driving or operating machinery.


Q: Can people with a history of heart issues or high blood pressure safely use Nodis?

Studies and official information indicate that Nodis is intended for use in adults to reduce the risk of major cardiovascular events. This includes patients who have not previously had heart disease but are identified as being at increased risk. Eligibility for the drug in individuals with a specific history of heart conditions is determined following a full medical assessment.


Q: What percentage of patients in the major studies showed improvement on Nodis?

Clinical studies examined the drug’s effectiveness in modifying blood fat biomarkers. The research indicates that Nodis reduced Low-Density Lipoprotein Cholesterol (LDL-C) levels by approximately 33% to 65% across the approved therapeutic dose range.


Q: Why is Nodis only available by prescription from a healthcare provider?

According to regulatory documents, the drug is a potent medicine that requires careful use. Its prescription status is necessary due to the need for professional supervision, which is required to assess individual risk factors, manage potential rare but serious side effects, and ensure appropriate medical supervision for its use.


Q: Is there a patient information leaflet (PIL) or consumer medical information (CMI) for Nodis I can read?

Yes, official consumer-facing information, such as a Consumer Medical Information (CMI) or Patient Information Leaflet (PIL), is based on and provided with official regulatory documents. These documents contain key safety and use information.


Q: What kind of monitoring (e.g., blood tests) might be needed while taking Nodis?

Official product information states that regular monitoring of the patient’s lipid profile is required to assess the effectiveness of the treatment. Official documents often note that liver enzyme tests are usually performed before starting therapy and may be repeated periodically.


Q: Is Nodis a cure for the condition or does it only help manage the symptoms?

Nodis is classified as a potent lipid-lowering agent. Its purpose is for the long-term management of high cholesterol and reduction of cardiovascular risk, consistent with its classification as a lipid-lowering agent.


Q: How quickly should I expect to feel the effects of Nodis after starting the treatment?

According to pharmacokinetic studies, the maximum concentration of the drug in the bloodstream is reached within a few hours after a dose. However, the clinical assessment of cholesterol-lowering efficacy is typically evaluated by blood tests approximately four weeks after treatment initiation.


Q: What is the typical timeframe before the full benefits of Nodis are noticed?

The timeframe for assessing the drug's full effect on cholesterol levels often aligns with the typical two to four weeks allowed before a dose adjustment is considered, based on clinical assessment of cholesterol levels.


Q: Is Nodis known to cause weight gain, weight loss, or changes in appetite?

Based on the safety data from clinical trials, changes in body weight or appetite are not listed as recognized adverse reactions reported for the medication.


Q: Can Nodis be taken with standard over-the-counter pain relievers like ibuprofen or acetaminophen?

No specific major drug interaction requiring a change in dose is formally listed for common non-prescription pain relievers like acetaminophen or ibuprofen. However, all co-administered drugs and supplements must be disclosed to a healthcare professional.


Q: What happens if I consume alcohol while taking Nodis?

Official warnings note that alcohol consumption, due to the drug’s potential hepatic (liver) effects, should be discussed with a professional. The combination may increase the risk of liver side effects.


Q: Is Nodis considered a controlled substance in any region?

Nodis is a prescription medicine, but it is not typically scheduled as a controlled substance by major regulatory bodies.


Q: Is it possible for Nodis to interact with dental procedures or local anesthesia?

The official safety profile advises that the surgical or dental team should be informed you are taking the drug. This is because some medicines used during procedures, including certain anesthetic agents, may require an assessment of the combination due to potential interactions.


Q: Can Nodis be taken with everyday vitamin supplements like Vitamin C or B12?

No clinically significant interactions are generally listed for standard vitamins like Vitamin C or B12. Nevertheless, all supplements, including vitamins and herbal products, must be disclosed to a healthcare professional for a complete safety assessment.


Q: Does Nodis carry a risk of physical or psychological dependence?

The drug is a lipid-lowering agent and is not associated with a risk of physical or psychological dependence.


Q: Why do some people experience initial sleep disturbances when they begin Nodis?

Regulatory safety reviews note that sleep disturbances, including insomnia (difficulty sleeping) and nightmares, have been reported in post-marketing experience for the statin class of medicines.


Q: Do you need to stop taking Nodis before having surgery?

Official guidance indicates that for many procedures, the drug is advised to be continued during both elective and emergency surgery. However, the final decision is made by the surgical and medical team after assessing individual risk factors.


Q: Is Nodis often used in combination with other drugs for the same condition?

The drug is indicated for use as adjunctive therapy, meaning it can be used alongside other lipid-lowering treatments. This combination use is often employed for patients with specific high-risk or inherited forms of high cholesterol.


Q: What other factors besides the drug itself can influence how well Nodis works?

Official product information states that Nodis is prescribed as an adjunct to diet. Its effectiveness is closely tied to the patient’s dietary habits, as the medication is prescribed as an adjunct to diet. Patient adherence to the prescribed regimen is also an important factor in therapeutic success.


Q: Is it possible for Nodis to affect or alter mood and emotional state?

Post-marketing safety reports for the statin class of drugs have included instances of neuropsychiatric effects, such as cognitive and behavioral changes. If these effects occur, they should be disclosed to a medical professional.

How should Nodis be stored and disposed of?

Official Storage and Disposal Profile (Based on Regulatory Analog)

The official regulatory documents for the analog product strictly mandate specific conditions to ensure product stability and integrity.

Storage Domain Official Requirement (Based on Labeling)
Temperature Must be stored in a freezer at -10 to -25 C.
Protection Protect from moisture and store in the original sealed sachet.
Handling Must be removed from the freezer just prior to use; Do not use sharp objects to open the packaging.
Shelf-Life Defined stability period of 3 years as packaged.
Disposal Any unused product or waste material must be disposed of in accordance with local regulatory requirements.

These official statements define a stringent storage profile requiring cold chain maintenance until administration. The packaging instructions are necessary to ensure the integrity of the retrieval system, and disposal must align with local governmental rules for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nodis found in:

A-Z Index: